Age-related Macular Degeneration The Disease
There are two types of AMD and they are referred to as wet or dry. Wet AMD occurs when blood vessels will appear growing from the choroid 
Who is Affected?
By far the biggest risk factor for developing AMD is age. 3 It is estimated that around eight million Americans age 54 and older will develop AMD and of those one million will develop advanced AMD. In the UK, 75 % of the individuals who go blind will do so because of the development of AMD. 5 This observation is somewhat tenuous with the exception of the link to smoking, which has been shown to be a positive risk factor in both diseases. According to recent research, white females are a stronger at risk group for development of the disease, but this is not supported by overall trends. 1, 6 There have been links to chronic obesity, especially in men, and smoking as a contributing factor for the development of AMD. Combinations of these factors including age increase the risk for disease development even more.
Other implied risk factors include hypertension, increased cholesterol levels, and elevated high-density lipoprotein (HDL) cholesterol. However, the scientific literature are not conclusive on these factors. As mentioned, an individual's genetic makeup has also been linked to development of AMD. The genes for factors H, B, and 3 have been linked to the disease.
These genes are part of the controlling mechanism of the complement activation system, and thus inflammation, which is a key sign of AMD.
Treatment Options Laser Surgery
Treatment with laser surgery can be successful in a limited number of cases provided certain conditions are met. Laser treatment may delay the development of choroid neovascularization by a few months in patients with unilateral advanced AMD. 7 But the symptomology will return in time.
Phototherapy
This is an option that has been used to treat wet AMD. The drug verteporfin is administered by intravenous injection followed by light treatment. 8 The combination of drug in the correct location in the eye causes destruction of the blood vessels and thus disease treatment. This method may correct acute problems, but will not affect the underlying disease issue. As with laser surgery, the disease progression may return in the form of blood vessel encroachment in the posterior segment.
Drug Therapy
The first approved AMD drug treatment was Macugen (pegaptanib).
Macugen is composed of messenger mRNA (mRNA), and has shown some benefit in patients. The risk is due to the actual administration of the drug.
Supplements
Supplements may also be used as treatment options. Lutein and zeaxanthin have been used to increase eye health specifically in the area of AMD.
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The compounds may be taken as dietary supplements or from eating and cataract. 12 The overall conclusions from the study were that while the supplements had no effect on cataract they were effective at preventing vision loss due to AMD. In a subsequent study Age-Related Eye Disease Study 2 (AREDS 2), lutein and zeaxanthin were evaluated for their ability to prevent AMD progression. 13 These supplements taken together were found to be an effective substitute for beta-carotene in modulating AMD disease progression.
Anti-AMD drugs delivered in drop form topically onto the surface of the cornea have not been shown to be effective at treating AMD. However, a recent study in animals have shown that Lucentis delivered via a hydrogel contact lens may be able to reach the retinal space of the eye. Increased public awareness coupled with better diagnostic techniques and improved treatment methods are the best techniques available at this time to prolong an individual's quality of life through the course of the disease. As product costs decline these current therapies should be more readily available for use. 16 n
